Setmelanotide Cuts BMI 19.8 Points Versus Placebo in Hypothalamic Obesity

The phase 3 TRANSCEND trial gives pharmacists the first randomized evidence that the melanocortin-4 receptor (MC4R) agonist setmelanotide reduces body mass and hunger in acquired hypothalamic obesity, along with a safety profile that depends on careful management of pituitary hormone replacement.

📅 Journal publication: Jul 9, 2026 · Last updated: Oct 13, 2026

setmelanotidemelanocortin-4 receptor agonistacquired hypothalamic obesitycraniopharyngiomaobesity pharmacotherapyrandomized controlled trialphase 3hungerBMIdesmopressinadrenal insufficiencyTRANSCEND Endocrinology / Diabetes / Obesity

Also in Nephrology

Background Information

Setmelanotide shows promise in reducing BMI in hypothalamic obesity.

Acquired hypothalamic obesity is challenging to manage and leads to significant weight gain and related health issues. Setmelanotide resulted in a 16.5% reduction in body mass index (BMI) compared to 3.3% with placebo and decreased hunger scores significantly. The study suggests setmelanotide may be an effective treatment for acquired hypothalamic obesity, but adverse events were common, highlighting the need for careful patient selection and monitoring. Setmelanotide shows promise in managing acquired hypothalamic obesity with significant BMI reduction.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Müller HL, Roth CL, TRANSCEND Trial Group

Citation: Miller JL, van Santen HM, Phillips SA, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. The New England journal of medicine. 2026;395(2):138-150. doi:10.1056/NEJMoa2512275

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →